Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Paradiso

Showing results (1-10 of 191) with videos related to

Pageof 20
Sort By:
Tumori|April 21, 2016
Application of OECI accreditation program to cancer institutes of the Alleanza Contro il Cancro Italian Network: a special project supported by the Italian Ministry of HealthAngelo Paradiso, Filippo Belardelli
Applied & Translational Genomics|June 9, 2016
Rare disease research: Breaking the privacy barrierDeborah Mascalzoni, Angelo Paradiso, Matts Hansson
International Journal of Oncology|November 8, 2005
Telomeres, telomerase and oral cancer (Review)Sinto Sebastian, Luciano Grammatica, Angelo Paradiso
Current Genomics|November 2, 2013
Mitochondria and familial predisposition to breast cancerStefania Weigl, Angelo Paradiso, Stefania Tommasi
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology|May 30, 2009
HCC heterogeneity: molecular pathogenesis and clinical implicationsEmilia Fransvea, Angelo Paradiso, Salvatore Antonaci, et al.
Cancer Genomics & Proteomics|June 25, 2020
Anticancer Effects of Nutraceuticals in the Mediterranean Diet: An Epigenetic Diet ModelRosa Divella, Antonella Daniele, Eufemia Savino, et al.
International Journal of Environmental Research and Public Health|April 23, 2020
COVID-19 Pandemic and the Crisis of Health Systems: The Experience of the Apulia Cancer Network and of the Comprehensive Cancer Center Istituto Tumori "Giovanni Paolo II" of BariNicola Silvestris, Antonio Moschetta, Angelo Paradiso, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2003
The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell linesJian-Ming Xu, Amalia Azzariti, Giuseppe Colucci, et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology|July 21, 2007
BRAF in papillary thyroid carcinomaSalvatore Giovanni Lanzilotta, Luciano Grammatica, Angelo Paradiso, et al.
Critical Reviews in Oncology/Hematology|March 11, 2011
Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009)Veronica Goffredo, Angelo Paradiso, Girolamo Ranieri, et al.
Pageof 20

Showing results (1-10 of 191) with videos related to

Sort By:
Pageof 20
Tumori|April 21, 2016
Application of OECI accreditation program to cancer institutes of the Alleanza Contro il Cancro Italian Network: a special project supported by the Italian Ministry of HealthAngelo Paradiso, Filippo Belardelli
Applied & Translational Genomics|June 9, 2016
Rare disease research: Breaking the privacy barrierDeborah Mascalzoni, Angelo Paradiso, Matts Hansson
International Journal of Oncology|November 8, 2005
Telomeres, telomerase and oral cancer (Review)Sinto Sebastian, Luciano Grammatica, Angelo Paradiso
Current Genomics|November 2, 2013
Mitochondria and familial predisposition to breast cancerStefania Weigl, Angelo Paradiso, Stefania Tommasi
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology|May 30, 2009
HCC heterogeneity: molecular pathogenesis and clinical implicationsEmilia Fransvea, Angelo Paradiso, Salvatore Antonaci, et al.
Cancer Genomics & Proteomics|June 25, 2020
Anticancer Effects of Nutraceuticals in the Mediterranean Diet: An Epigenetic Diet ModelRosa Divella, Antonella Daniele, Eufemia Savino, et al.
International Journal of Environmental Research and Public Health|April 23, 2020
COVID-19 Pandemic and the Crisis of Health Systems: The Experience of the Apulia Cancer Network and of the Comprehensive Cancer Center Istituto Tumori "Giovanni Paolo II" of BariNicola Silvestris, Antonio Moschetta, Angelo Paradiso, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2003
The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell linesJian-Ming Xu, Amalia Azzariti, Giuseppe Colucci, et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology|July 21, 2007
BRAF in papillary thyroid carcinomaSalvatore Giovanni Lanzilotta, Luciano Grammatica, Angelo Paradiso, et al.
Critical Reviews in Oncology/Hematology|March 11, 2011
Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009)Veronica Goffredo, Angelo Paradiso, Girolamo Ranieri, et al.
Pageof 20